NeuroSense Therapeutics (NRSN) Competitors $1.36 +0.08 (+6.25%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends NRSN vs. RLYB, GANX, SCYX, QTTB, XLO, CLNN, ATNM, GRCE, LEXX, and CALCShould you be buying NeuroSense Therapeutics stock or one of its competitors? The main competitors of NeuroSense Therapeutics include Rallybio (RLYB), Gain Therapeutics (GANX), SCYNEXIS (SCYX), Q32 Bio (QTTB), Xilio Therapeutics (XLO), Clene (CLNN), Actinium Pharmaceuticals (ATNM), Grace Therapeutics (GRCE), Lexaria Bioscience (LEXX), and CalciMedica (CALC). These companies are all part of the "pharmaceutical preparations" industry. NeuroSense Therapeutics vs. Rallybio Gain Therapeutics SCYNEXIS Q32 Bio Xilio Therapeutics Clene Actinium Pharmaceuticals Grace Therapeutics Lexaria Bioscience CalciMedica NeuroSense Therapeutics (NASDAQ:NRSN) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, community ranking, valuation, profitability, risk, dividends, earnings and analyst recommendations. Do analysts prefer NRSN or RLYB? Rallybio has a consensus price target of $9.75, suggesting a potential upside of 926.32%. Given Rallybio's stronger consensus rating and higher possible upside, analysts plainly believe Rallybio is more favorable than NeuroSense Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeuroSense Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Rallybio 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67 Do institutionals & insiders hold more shares of NRSN or RLYB? 1.0% of NeuroSense Therapeutics shares are owned by institutional investors. Comparatively, 90.3% of Rallybio shares are owned by institutional investors. 27.4% of NeuroSense Therapeutics shares are owned by insiders. Comparatively, 7.4% of Rallybio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is NRSN or RLYB more profitable? NeuroSense Therapeutics' return on equity of 0.00% beat Rallybio's return on equity.Company Net Margins Return on Equity Return on Assets NeuroSense TherapeuticsN/A N/A -286.31% Rallybio N/A -77.39%-69.33% Does the media favor NRSN or RLYB? In the previous week, NeuroSense Therapeutics had 10 more articles in the media than Rallybio. MarketBeat recorded 10 mentions for NeuroSense Therapeutics and 0 mentions for Rallybio. NeuroSense Therapeutics' average media sentiment score of 0.20 beat Rallybio's score of 0.00 indicating that NeuroSense Therapeutics is being referred to more favorably in the media. Company Overall Sentiment NeuroSense Therapeutics Neutral Rallybio Neutral Which has stronger valuation and earnings, NRSN or RLYB? NeuroSense Therapeutics has higher earnings, but lower revenue than Rallybio. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuroSense TherapeuticsN/AN/A-$11.28M-$0.85-1.60Rallybio$598K65.91-$74.56M-$1.60-0.59 Does the MarketBeat Community believe in NRSN or RLYB? Rallybio received 39 more outperform votes than NeuroSense Therapeutics when rated by MarketBeat users. Likewise, 77.36% of users gave Rallybio an outperform vote while only 66.67% of users gave NeuroSense Therapeutics an outperform vote. CompanyUnderperformOutperformNeuroSense TherapeuticsOutperform Votes266.67% Underperform Votes133.33% RallybioOutperform Votes4177.36% Underperform Votes1222.64% Which has more volatility & risk, NRSN or RLYB? NeuroSense Therapeutics has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500. Comparatively, Rallybio has a beta of -1.55, meaning that its stock price is 255% less volatile than the S&P 500. SummaryRallybio beats NeuroSense Therapeutics on 9 of the 16 factors compared between the two stocks. Ad InvestorPlaceWall Street Icon: “You must get on the right side of this thing”I created one of the first quantitative analysis-based stock picking systems long before "quants" became a thing on Wall Street… leading Forbes to call me "King of the Quants." I'm writing to you today because my system has recently uncovered a market phenomenon I haven't seen in 30 years.This market shakeup is going to be much more intense. Get NeuroSense Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRSN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRSN vs. The Competition Export to ExcelMetricNeuroSense TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.59M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-1.6010.5589.7417.16Price / SalesN/A196.061,117.09117.04Price / CashN/A57.1643.1037.86Price / Book-9.715.094.784.78Net Income-$11.28M$151.83M$120.31M$225.60M7 Day Performance58.14%-2.14%-1.92%-1.23%1 Month Performance51.11%-4.56%13.65%0.46%1 Year Performance75.33%8.87%28.34%15.24% NeuroSense Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRSNNeuroSense Therapeutics0.4862 of 5 stars$1.36+6.3%N/A+75.0%$18.59MN/A-1.6018Earnings ReportGap DownHigh Trading VolumeRLYBRallybio2.6948 of 5 stars$1.05-2.8%$9.75+828.6%-63.6%$43.56MN/A-0.6740GANXGain Therapeutics2.6687 of 5 stars$1.63flat$7.25+344.8%-37.6%$43.24M$50,000.00-1.4820SCYXSCYNEXIS0.8217 of 5 stars$1.12-1.5%N/A-46.5%$42.61M$8.57M-1.5460Gap DownQTTBQ32 Bio2.8291 of 5 stars$3.41-7.8%$29.86+775.6%N/A$41.54M$-6,651,000.00-0.2439High Trading VolumeXLOXilio Therapeutics2.7965 of 5 stars$0.92-4.7%$4.00+333.1%+140.9%$40.60MN/A-0.5473News CoverageGap UpCLNNClene3.73 of 5 stars$4.74-4.2%$55.25+1,065.6%-30.2%$39.63M$650,000.00-0.94100Analyst ForecastNews CoverageATNMActinium Pharmaceuticals1.2441 of 5 stars$1.25+1.2%$7.40+494.4%N/A$38.84M$81,000.00-0.8849GRCEGrace TherapeuticsN/A$3.83+7.0%N/AN/A$38.84MN/A-3.54N/APositive NewsLEXXLexaria Bioscience3.1487 of 5 stars$2.22-0.9%$11.00+395.5%+66.4%$38.75M$464,278.00-4.777CALCCalciMedica2.9477 of 5 stars$2.83+3.7%$19.33+583.2%-7.1%$38.15MN/A-2.5330Positive News Related Companies and Tools Related Companies RLYB Competitors GANX Competitors SCYX Competitors QTTB Competitors XLO Competitors CLNN Competitors ATNM Competitors GRCE Competitors LEXX Competitors CALC Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NRSN) was last updated on 12/22/2024 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroSense Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroSense Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NRSN Stock Alerts